NOTE: This video is ONLY available to watch in selected countries and geographies
In a late-breaking Podium 1st presentation at the 2022 Charing Cross (CX) International Symposium (26–28 April, London, UK), Andrew Holden (Auckland, New Zealand) revealed that patients treated in the drug-coated balloon (DCB) arm of the IN.PACT AV Access trial remained intervention-free for longer than those who received a standard percutaneous transluminal angioplasty (PTA). Click on the video for the full presentation.
Holden told delegates that end-stage kidney disease patients in IN.PACT AV Access had a median time to reintervention that was 14.7 months longer when they were treated with DCB compared to PTA and that there were no safety concerns. As such, Holden added, these findings represent durable long-term data supporting the use of the IN.PACT DCB as “a standard of care” for AVF maintenance in this patient population.
This video is sponsored by Medtronic.
